Fluticasone furoate nasal spray: Effective monotherapy for symptoms of perennial allergic rhinitis in adults/adolescents

Allergy and Asthma Proceedings

Volumn 29, Issue 3, 2008, Pages 313-321

  Vasar, Maire ^a,g   Houle, Pierre Alain ^b   Douglass, Jo Anne ^c   Meltzer, Eli O ^d   Silvey, MaryJane ^e   Wu, Wei ^e   Caldwell, Mark ^f   Philpot, Edward ^{a,b,c,d,e,f,g}  

^a UNIVERSITY OF TARTU   (Estonia)

^b MCGILL UNIVERSITY   (Canada)

^c MONASH UNIVERSITY   (Australia)

^d ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^e GLAXOSMITHKLINE   (United States)

^f GLAXOSMITHKLINE   (United Kingdom)

^g TARTU UNIVERSITY HOSPITAL   (Estonia)

Author keywords

Efficacy; Fluticasone furoate nasal spray; Intranasal corticosteroid; Nasal symptoms; Naso ocular reflex; Ocular symptoms; Perennial allergic rhinitis; Quality of life; Randomized controlled trial; Safety

Indexed keywords

ANDROSTANE DERIVATIVE; FLUTICASONE FUROATE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LACRIMAL DUCT; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PERENNIAL RHINITIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ANDROSTADIENES; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; NASOLACRIMAL DUCT; QUALITY OF LIFE; QUESTIONNAIRES; RHINITIS, ALLERGIC, PERENNIAL; SPIROMETRY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 46649098669     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap.2008.29.3126     Document Type: Article

References (31)

1. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: Complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 81:478-518, 1998.
2. Bauchau V, and Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy 60:350-353, 2005.
3. van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 55:116-134, 2000.
4. Demoly P, Allaert FA, and Lecasble M. ERASM, a pharmacoepidemiologic survey on management of intermittent allergic rhinitis in every day general medical practice in France. Allergy 57:546-554, 2002.
5. Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 368:733-743, 2006.
6. Sly RM. Epidemiology of allergic rhinitis. Clin Rev Allergy Immunol 22:67-103, 2002.
7. Bousquet J, van Cauwenberge P, and Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108(5 Suppl):S147-S334, 2001.
8. Task Force on Allergic Disorders. The Allergy Report, Vol. 1. 2000. Milwaukee, WI: American Academy of Allergy, Asthma and Immunology. Available online at www.theallergyreport. com; accessed June 21, 2007.
9. International Rhinitis Management Working Group. International consensus report on the diagnosis and management of rhinitis. Allergy 49(19 Suppl):1-34, 1994.
10. O'Connor RD, and Punekar YS. Assessing symptomatic burden of patients suffering from allergic rhinitis (AR). J Allergy Clin Immunol 117(suppl S):S322, 2006.
11. Craig TJ, McCann JL, Gurevich F et al. The correlation between allergic rhinitis and sleep disturbance. J Allergy Clin Immunol 114(5 Suppl):S139-S145, 2004.
12. Smolensky MH, Reinberg A, and Labrecque G. Twenty-four hour pattern in symptom intensity of viral and allergic rhinitis: Treatment implications. J Allergy Clin Immunol 95: 1084-1096, 1995.
13. Mandl M, Nolop K, and Lutsky BN. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. The 194-079 Study Group. Ann Allergy Asthma Immunol 79:370-378, 1997.
14. van As A, Bronsky EA, Dockhorn RJ, et al. Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone diproprionate. J Allergy Clin Immunol 91:1146-1154, 1993.
15. Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol 293:L660-L667, 2007.
16. Allen A, Down G, Newland A, et al. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects. Clin Ther 29:1415-1420, 2007.
17. Rosenblut A, Bardin PG, Muller B, et al. Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy 62:1071-1077, 2007.
18. Kaiser HB, Naclerio RM, Given J, et al. Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 119:1430-1437, 2007.
19. Martin BG, Ratner PH, Hampel FC, et al. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc 28:216-225, 2007.
20. Fokkens WJ, Jogi R, Reinartz S, et al. Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Allergy 62:1078-1084, 2007.
21. Berger WE, Godfrey JW, and Slater AL. Intranasal corticosteroids: The development of a drug delivery device for fluticasone furoate as a potential step toward improved compliance. Expert Opin Drug Deliv 4:689-701, 2007.
22. National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the diagnosis and management of asthma: Update on selected topics. 2002. U.S. Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD.
23. Global Initiative for Asthma (GINA). Global Initiative for Asthma (GINA) Guidelines. Available online at www.ginasthma.com; accessed October 14, 2007.
24. Lemiere C, Bai T, Balter M, et al. Adult asthma consensus guidelines update 2003. Can Respir J 11(Suppl A):9A-18A, 2004.
25. Juniper EF, Guyatt GH, and Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: Development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 93:413-423, 1994.
26. Nathan RA, Berger W, Yang W, et al. Once-daily fluticasone furoate nasal spray relieves nasal symptoms in adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2008. In press.
27. Baroody FM, Foster KA, Markaryan A, et al. Nasal ocular reflexes and eye symptoms in patients with allergic rhinitis. Ann Allergy Asthma Immunol 100:194-199, 2008.
28. van Bavel JH, Toler T, Ellsworth A, et al. Once-daily fluticasone furoate nasal spray (FFNS) improves quality of life (QoL) in subjects with seasonal allergic rhinitis (SAR) during the mountain cedar pollen season. J Allergy Clin Immunol 119(suppl S):S230, 2007.
29. Waddell AN, Fatel SK, Toma AG, et al. Intranasal steroid sprays in the treatment of rhinitis: is one better than another? J Laryngol Otol 117:843-845, 2003.
30. Creticos P, Fireman P, Settipane G, et al. Intranasal budesonide aqueous pump spray (Rhinocort Aqua) for the treatment of seasonal allergic rhinitis. Rhinocort Aqua Study Group. Allergy Asthma Proc 19:285-294, 1998.
31. Banov CH, Woehler TR, LaForce CF, et al. Once daily intranasal fluticasone propionate is effective for perennial allergic rhinitis. Ann Allergy 73:240-246, 1994.